- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Wayne J. Katon, MD, Discusses How Collaborative Care Drives Quality
Wayne J. Katon, MD, professor of psychiatry, director of the division of health services and epidemiology, and vice chair of the department of psychiatry and behavioral sciences at the University of Washington Medical School, says that people with psychiatric illness in primary care settings cost the system twice as much as those without mental illness. Comorbidities such as depression can add to those costs.
Wayne J. Katon, MD, professor of psychiatry, director of the division of health services and epidemiology, and vice chair of the department of psychiatry and behavioral sciences at the University of Washington Medical School, says that people with psychiatric illness in primary care settings cost the system twice as much as those without mental illness. Comorbidities such as depression can add to those costs.
“Integrating models of care like collaborative care have been shown to improve the quality of care, meaning they’re more likely to get an evidence-based treatment like a psychotherapy or med that would help their depression, and also they have better outcomes,” says Dr Katon. “We’ve shown that you can actually save money, particularly with these comorbid populations, by providing better mental healthcare integrated within the primary care system.”
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
